Evidence map›Paper›PMID 36838960›Full record

ReviewMolecules (Basel, Switzerland)2023

The Impact of Fluorination on the Design of Histone Deacetylase Inhibitors.

Duong Tien Anh, Nguyen Hai Nam, Brigitte Kircher, Daniel Baecker

Abstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Suzetrigine, a NaMolecules (Basel, Switzerland) · 2026
    Review
  2. Article
  3. Monofluoromethylation ofInternational journal of molecular sciences · 2023
    Review
  4. Bioorganic Chemistry: Current and Future Perspectives.Molecules (Basel, Switzerland) · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Duong Tien AnhDepartment of Pharmaceutical Chemistry, Hanoi University of Pharmacy, 13-15 Le Thanh Tong, Hanoi 10000, Vietnam.ORCID 0000-0002-0695-7992
Nguyen Hai NamDepartment of Pharmaceutical Chemistry, Hanoi University of Pharmacy, 13-15 Le Thanh Tong, Hanoi 10000, Vietnam.
Brigitte KircherImmunobiology and Stem Cell Laboratory, Department of Internal Medicine V (Hematology and Oncology), Medical University Innsbruck, Anichstraße 35, 6020 Innsbruck, Austria.ORCID 0000-0003-1624-2664
Daniel BaeckerDepartment of Pharmaceutical and Medicinal Chemistry, Institute of Pharmacy, University of Greifswald, Friedrich-Ludwig-Jahn-Straße 17, 17489 Greifswald, Germany.ORCID 0000-0002-1963-9838

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent years, histone deacetylases (HDACs) have emerged as promising targets in the treatment of cancer. The approach is to inhibit HDACs with drugs known as HDAC inhibitors (HDACis). Such HDACis are broadly classified according to their chemical structure, e.g., hydroxamic acids, benzamides, thiols, short-chain fatty acids, and cyclic peptides. Fluorination plays an important role in the medicinal-chemical design of new active representatives. As a result of the introduction of fluorine into the chemical structure, parameters such as potency or selectivity towards isoforms of HDACs can be increased. However, the impact of fluorination cannot always be clearly deduced. Nevertheless, a change in lipophilicity and, hence, solubility, as well as permeability, can influence the potency. The selectivity towards certain HDACs isoforms can be explained by special interactions of fluorinated compounds with the structure of the slightly different enzymes. Another aspect is that for a more detailed investigation of newly synthesized fluorine-containing active compounds, fluorination is often used for the purpose of labeling. Aside from the isotope

Indexed as

FluorineHistone Deacetylase InhibitorsHalogenationHistone DeacetylasesHydroxamic AcidsProtein IsoformsFluorineHistone Deacetylase InhibitorsHistone DeacetylasesHydroxamic AcidsProtein Isoformsfluorinationfluorinefluorine-18histone deacetylase (HDAC)histone deacetylase inhibitors (HDACis)positron emission tomography (PET)potencyselectivitysuberoylanilide hydroxamic acid (SAHA)vorinostat

Identifiers

PMID36838960
PMCPMC9965134

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.